The costs and benefits were combined to give a cost per QALY.
The average cost per QALY was $22,831 (95% CI: 19,659 - 50,567) in the VXR group and $25,148 (95% CI: 20,856 - 57,013) in the SSRI group.
The incremental cost-effectiveness ratio for VXR compared with SSRI was $12,611 (95% CI: 8,964 - 36,383).
The 95% CI were estimated ranges based upon the sensitivity analysis performed using Monte Carlo simulation.